You are currently viewing a new version of our website. To view the old version click .

Cancers, Volume 16, Issue 6

March-2 2024 - 165 articles

Cover Story: The BCL2 inhibitor venetoclax combined with the hypomethylating agent azacitidine is the new therapeutic standard for elderly or unfit acute myeloid leukemia patients. Despite a 65% composite response rate, overall survival is about 14 months, underlying the need for new therapeutics with improved efficacy and low toxicity. Gene mutations associated with resistance or relapse are TP53, signaling mutations, and the newly described BAX mutations. Venetoclax-based triplet therapies, including IDH and FLT3 inhibitors or menin inhibitors, are under investigation to improve patient outcomes. A better comprehension of genomic and non-genomic evolution upon treatment and the interplay between genomic alterations and apoptosis will allow us to tackle resistance mechanisms in the future. View this paper
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (165)

  • Article
  • Open Access
2 Citations
2,464 Views
15 Pages

Quality of Life, Sarcopenia and Nutritional Status in Patients with Esophagogastric Tumors before and after Neoadjuvant Therapy

  • Lena Schooren,
  • Grace H. Oberhoff,
  • Alexander Koch,
  • Andreas Kroh,
  • Tom F. Ulmer,
  • Florian Vondran,
  • Jan Bednarsch,
  • Ulf P. Neumann,
  • Sophia M. Schmitz and
  • Patrick H. Alizai

21 March 2024

(1) Background: Health-related quality of life (HRQoL) gains importance as novel treatment options for individuals with esophagogastric tumors to improve long-term survival. Impaired HRQoL has been shown to be a predictor of overall survival. Sarcope...

  • Article
  • Open Access
3,201 Views
12 Pages

Treatment Strategies for Glioblastoma in the Elderly: What Should We Focus on Compared to Younger Patients

  • Hanah Hadice Gull,
  • Antonia Carlotta Von Riegen,
  • Greta Theresa Beckmann,
  • Pikria Ketelauri,
  • Sebastian Walbrodt,
  • Alejandro N. Santos,
  • Christoph Oster,
  • Teresa Schmidt,
  • Martin Glas and
  • Ramazan Jabbarli
  • + 5 authors

21 March 2024

(1) Background: Although the incidence of glioblastoma (GB) has a peak in patients aged 75–84 years, no standard treatment regimen for elderly patients has been established so far. The goal of this study was to analyze the outcome of GB patient...

  • Correction
  • Open Access
1,495 Views
3 Pages

Correction: Zwergel et al. Novel Quinoline Compounds Active in Cancer Cells through Coupled DNA Methyltransferase Inhibition and Degradation. Cancers 2020, 12, 447

  • Clemens Zwergel,
  • Rossella Fioravanti,
  • Giulia Stazi,
  • Federica Sarno,
  • Cecilia Battistelli,
  • Annalisa Romanelli,
  • Angela Nebbioso,
  • Eduarda Mendes,
  • Alexandra Paulo and
  • Raffaele Strippoli
  • + 9 authors

21 March 2024

In the original publication [...]

  • Article
  • Open Access
1,791 Views
12 Pages

Preliminary Experience with Virtual Monoenergetic Imaging and Iodine Mapping in the Primary Staging of Endometrial Cancer

  • Stephanie Tina Sauer,
  • Henner Huflage,
  • Sara Aniki Christner,
  • Theresa Sophie Patzer,
  • Matthias Kiesel,
  • Anne Quenzer,
  • Andreas Steven Kunz,
  • Thorsten Alexander Bley and
  • Jan-Peter Grunz

20 March 2024

This study investigated whether virtual monoenergetic images (VMIs) and iodine mapping based on dual-energy CT (DECT) provide advantages in the assessment of endometrial cancer. A dual-source DECT was performed for primary staging of histologically p...

  • Article
  • Open Access
10 Citations
5,088 Views
16 Pages

Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study

  • Francesca Romana Mauro,
  • Potito Rosario Scalzulli,
  • Lydia Scarfò,
  • Carla Minoia,
  • Roberta Murru,
  • Paolo Sportoletti,
  • Ferdinando Frigeri,
  • Francesco Albano,
  • Nicola Di Renzo and
  • Alessandro Sanna
  • + 32 authors

20 March 2024

Real-world data in clinical practice are needed to confirm the efficacy and safety that ibrutinib has demonstrated in clinical trials of patients with chronic lymphocytic leukemia (CLL). We described the real-world persistence rate, patterns of use,...

  • Article
  • Open Access
4 Citations
2,409 Views
18 Pages

T-Cell Subtypes and Immune Signatures in Cutaneous Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy

  • Magdalena Absmaier-Kijak,
  • Caterina Iuliano,
  • Susanne Kaesler,
  • Tilo Biedermann,
  • Christian Posch and
  • Knut Brockow

20 March 2024

Immune checkpoint inhibition (ICI) improves outcomes in melanoma patients, but associated T-cell activation frequently leads to immune-related cutaneous adverse events (cutAEs). To dynamically identify T-cell subtypes and immune signatures associated...

  • Article
  • Open Access
6 Citations
4,482 Views
17 Pages

HER2 and PD-L1 Expression in Gastric and Gastroesophageal Junction Cancer: Insights for Combinatorial Targeting Approaches

  • Marta Baptista Freitas,
  • Irene Gullo,
  • Dina Leitão,
  • Lúcia Águas,
  • Carla Oliveira,
  • António Polónia,
  • Joana Gomes,
  • Fátima Carneiro,
  • Celso Albuquerque Reis and
  • Henrique Oliveira Duarte

20 March 2024

Gastric and gastroesophageal junction adenocarcinomas (GA/GEJA) are associated with a poor prognosis, primarily due to late disease diagnosis. Human Epidermal Growth Factor Receptor 2 (HER2) overexpression and programmed death-ligand 1 (PD-L1) expres...

  • Review
  • Open Access
16 Citations
5,477 Views
24 Pages

Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors

  • Ben Ponvilawan,
  • Abdul Wali Khan,
  • Janakiraman Subramanian and
  • Dhruv Bansal

20 March 2024

Immune-related adverse events (irAEs) are the most common complication of immune checkpoint inhibitor (ICI) therapy. With the widespread use of ICIs in patients with solid tumors, up to 40% of the patients develop irAEs within five months of treatmen...

  • Article
  • Open Access
2 Citations
1,984 Views
12 Pages

Early Results of a Screening Program for Skin Cancer in Liver Transplant Recipients: A Cohort Study

  • Delal Akdag,
  • Allan Rasmussen,
  • Susanne Dam Nielsen,
  • Dina Leth Møller,
  • Katrine Togsverd-Bo,
  • Emily Wenande,
  • Merete Haedersdal and
  • Hans-Christian Pommergaard

20 March 2024

(1) Background: Skin cancer is the most common cancer in transplant recipients. Timely and regular screening may reduce advanced disease. The study aimed to determine referral rates to screening, the incidence, and risk factors of skin cancer in a Da...

  • Article
  • Open Access
4 Citations
2,478 Views
18 Pages

Proteomic Profiling of Cerebrospinal Fluid and Its Extracellular Vesicles from Extraventricular Drainage in Pediatric Pilocytic Astrocytoma, towards Precision Oncology

  • Sonia Spinelli,
  • Xhuliana Kajana,
  • Andrea Garbarino,
  • Martina Bartolucci,
  • Andrea Petretto,
  • Marco Pavanello,
  • Enrico Verrina,
  • Giovanni Candiano,
  • Isabella Panfoli and
  • Maurizio Bruschi

20 March 2024

Pediatric pilocytic astrocytoma (PA) is the most common brain tumor in children. Complete resection provides a favorable prognosis, except for unresectable PA forms. There is an incomplete understanding of the molecular and cellular pathogenesis of P...

of 17

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Cancers - ISSN 2072-6694